Prometheus Biosciences, Inc.
Prometheus Biosciences, Inc. (RXDX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · RXDX · as of Jun 30, 2023
Ownership Breakdown
3
Institutional Holders
▼ 239 vs Q1
$2.75M
Total Inst. Value
▼ $4.35B vs Q1
47.81M
Shares Outstanding
freeFloat 69.50%
25,622
13F Shares Held
▼ 40.53M vs Q1
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
RXDX largest shareholders · institutional ownership
Q2 2023 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
UBS ASSET MANAGEMENT AMERICAS INC pharmaceutical preparations | 18.4K | 3.89% | 3.89% | $1.98B | Aug 11, 2023 | — held |
TEACHER RETIREMENT SYSTEM OF TEXAS pharmaceutical preparations | 7.2K | 1.51% | 1.51% | $769.00M | Jul 17, 2023 | — held |
FINTRUST CAPITAL ADVISORS, LLC pharmaceutical preparations | 13 | 0.00% | 0.00% | $1.43M | Jul 25, 2023 | — held |
JPMORGAN CHASE & CO pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 11, 2023 | EXIT |
HUNTINGTON NATIONAL BANK pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 11, 2023 | EXIT |
JENNISON ASSOCIATES LLC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 3, 2023 | EXIT |
FRANKLIN RESOURCES INC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 11, 2023 | EXIT |
WELLS FARGO & COMPANY/MN pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 15, 2023 | EXIT |
NORTHERN TRUST CORP pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 11, 2023 | EXIT |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 14, 2023 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q2 2023 vs prior quarter
Q2 2023
0
Increased
+0 shares0
New Positions
first time holders0
Decreased
−0 shares47
Sold Out
fully exitedNet shares change (top 50)
+0
+0 / −0
Net new holders
-47
0 new / 47 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
RXDX insider trading · insider activity
Source: SEC Form 4
13
Buy transactions
56
Sell transactions
0.23
Buy/Sell ratio
$4M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Hendrix Martin director | Jun 16, 2023 | D-Return | 40,000 | $22.48 | $899.2K | 0 | Form 4 ↗ |
Hendrix Martin director | Jun 16, 2023 | D-Return | 20,500 | $29.02 | $594.9K | 0 | Form 4 ↗ |
Hendrix Martin director | Jun 16, 2023 | D-Return | 2,071 | $200.00 | $414.2K | 0 | Form 4 ↗ |
Laur James director | Jun 16, 2023 | D-Return | 20,500 | $29.02 | $594.9K | 0 | Form 4 ↗ |
Laur James director | Jun 16, 2023 | D-Return | 2,071 | $200.00 | $414.2K | 0 | Form 4 ↗ |
Laur James director | Jun 16, 2023 | D-Return | 40,000 | $22.48 | $899.2K | 0 | Form 4 ↗ |
Stenhouse Mark Chief Operating Officer | Jun 16, 2023 | D-Return | 34,085 | $110.20 | $3.76M | 0 | Form 4 ↗ |
Stenhouse Mark Chief Operating Officer | Jun 16, 2023 | D-Return | 40,000 | $0.50 | $20.0K | 0 | Form 4 ↗ |
Stenhouse Mark Chief Operating Officer | Jun 16, 2023 | D-Return | 70,371 | $36.32 | $2.56M | 0 | Form 4 ↗ |
Stenhouse Mark Chief Operating Officer | Jun 16, 2023 | D-Return | 240,000 | $6.70 | $1.61M | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Prometheus Biosciences, Inc. (RXDX) is primarily owned by institutional investors, who hold approximately 0.1% of total shares outstanding. Company insiders own approximately 30.50%, while retail and public investors account for the remaining 69.45%.
The largest institutional shareholder of Prometheus Biosciences, Inc. is UBS ASSET MANAGEMENT AMERICAS INC, holding approximately 18,448 shares — equal to 3.89% of outstanding shares — as of June 30, 2023.
A total of 3 institutional investors currently hold RXDX stock, with a combined institutional value of approximately $2,750,268 as of the most recent 13F filing period.
Frequently asked questions
RXDX ownershipPrometheus Biosciences, Inc. (RXDX) is primarily owned by institutional investors, who hold approximately 0.1% of shares. The largest shareholder is UBS ASSET MANAGEMENT AMERICAS INC with a 3.89% stake. Company insiders hold 30.50%. Data sourced from SEC Form 13F as of June 30, 2023.